LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN

ConclusionIn CASPIAN, the incidence of ADA to D was low and the safety profile of D+EP was consistent with previous reports of both D and EP.Clinical trial identificationNCT03043872 (release date: February 6, 2017).Editorial acknowledgementMedical writing support, which was in accordance with Good Publication Practice (GPP3) guidelines, was provided by Craig Turner, MSc, of Cirrus Communications (Macclesfield, UK), an Ashfield company, and was funded by AstraZeneca.Legal entity responsible for the studyAstraZeneca PLC.FundingAstraZeneca.DisclosureM. Özgüroğlu: Advisory / Consultancy, Advisory board participation: Janssen / Sanofi / Astellas; Honoraria (self): Novartis / Roche / Janssen / Sanofi / Astellas; Travel / Accommodation / Expenses: Bristol-Myers Squibb / Janssen. J.W. Goldman: Advisory / Consultancy: AstraZeneca / Genentech / Lilly; Research grant / Funding (self): AstraZeneca/MedImmune / Eli Lilly / Genentech / Bristol-Myers Squibb / Array BioPharma / Celgene / AbbVie; Speaker Bureau / Expert testimony: Merck. N. Reinmuth: Travel / Accommodation / Expenses, Personal fees and non-financial support: AstraZeneca / Boehringer-Ing elheim / Hoffmann La-Roche / Bristol-Myers Squibb / Pfizer; Non-remunerated activity/ies, Non-financial support: Abbvie; Travel / Accommodation / Expenses, Personal fees: MSD Sharp& Dohme / Takeda. Y. Chen: Research grant / Funding (self): AstraZeneca / ISPEN / Roche / Bristol-Myers Squibb; Travel / Accommodation / Expenses, Personal fee...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research